Relmada Therapeutics, Inc. (RLMD)

Relmada Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	3.86	4.09	5.4	44.44	2.5
Short-Term Investments	41.05	92.23	142.93	167.47	114.6
Cash & Short-Term Investments	44.91	96.32	148.32	211.91	117.09
Cash Growth	-53.38%	-35.06%	-30.01%	80.98%	0.56%
Other Receivables	-	-	0.51	0.09	0.08
Receivables	-	-	0.51	0.09	0.08
Prepaid Expenses	0.89	1.19	4.04	11.3	0.9
Total Current Assets	45.8	97.51	152.87	223.3	118.07
Property, Plant & Equipment	-	-	-	-	0
Other Long-Term Assets	0.02	0.04	0.03	0.03	0.11
Total Assets	45.82	97.55	152.91	223.33	118.19
Accounts Payable	4.13	3.51	5.26	11.19	8.35
Accrued Expenses	6.16	8.69	7.21	3.87	4.26
Total Current Liabilities	10.29	12.19	12.47	15.06	12.6
Other Long-Term Liabilities	0	-	-	-	-
Total Liabilities	10.3	12.19	12.47	15.06	12.6
Common Stock	0.03	0.03	0.03	0.03	0.02
Additional Paid-In Capital	676.37	646.23	602.52	513.3	284.88
Retained Earnings	-640.88	-560.9	-462.11	-305.07	-179.32
Total Common Equity	35.52	85.36	140.44	208.26	105.58
Shareholders' Equity	35.52	85.36	140.44	208.26	105.58
Total Liabilities & Equity	45.82	97.55	152.91	223.33	118.19
Net Cash (Debt)	44.91	96.32	148.32	211.91	117.09
Net Cash Growth	-53.38%	-35.06%	-30.01%	80.98%	0.65%
Net Cash Per Share	1.49	3.20	5.01	12.07	7.51
Filing Date Shares Outstanding	33.19	30.17	30.1	29.37	16.75
Total Common Shares Outstanding	30.1	30.1	30.1	27.74	16.33
Working Capital	35.5	85.31	140.4	208.24	105.47
Book Value Per Share	1.18	2.84	4.67	7.51	6.46
Tangible Book Value	35.52	85.36	140.44	208.26	105.58
Tangible Book Value Per Share	1.18	2.84	4.67	7.51	6.46

Updated Nov 7, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q